Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD

17

Apr 2026

Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global public health challenge with rapidly rising prevalence, especially in China. Despite advances in treatment, the underlying molecular mechanisms remain incompletely understood. A new research article published in the Chinese Medical Journal on March 16, 2026, provides critical insights into the role of exosomal microRNAs (miRNAs) in MASLD pathogenesis.

Therapy access could tackle joblessness

17

Apr 2026

Therapy access could tackle joblessness

Expanding access to NHS Talking Therapies may help reduce the long-term economic inactivity faced by people with entrenched mental health problems, University of Manchester researchers say.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.